Australian antiviral drug development company Island Pharmaceuticals (ASX:ILA) has announced new data that are expected to introduce significant, quantifiable time and cost savings into its clinical program for dengue fever.
Island Pharmaceuticals says new data leads to ISLA-101 Phase 2 study changes
June 3, 2024 Australian Biotech
Latest Video
New Stories
-
A mixed bag for the industry in Trump executive order on medicine pricing
April 17, 2025 - - Latest News -
Telix says IPAX-Linz study shows promising efficacy for glioma therapy candidate
April 16, 2025 - - Australian Biotech -
Prescient's PTX-100 receives US FDA Fast Track Designation
April 16, 2025 - - Australian Biotech -
Australian research finds turning off protein may help prevent liver cancer
April 16, 2025 - - Australian Biotech -
UQ tests vaccine response in CEPI-backed 150-day ‘moonshot’ challenge
April 16, 2025 - - Australian Biotech -
Cartherics announces board changes, including a new chair
April 16, 2025 - - Australian Biotech -
Astellas Pharma Australia appoints new head of medical affairs
April 16, 2025 - - Latest News